» Articles » PMID: 28162910

Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling

Overview
Journal Trends Mol Med
Date 2017 Feb 7
PMID 28162910
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Over recent decades anti-angiogenic therapies (AATs) have produced promising results in the treatment of different malignancies. Unfortunately, resistance often develops and patients ultimately relapse. In an attempt to elucidate the causes of recurrence, most studies have focused on tumor responses to hypoxic conditions induced by AAT. However, strategies targeting these mechanisms of resistance are still failing to improve treatments. Furthermore, a potential direct impact of AAT on tumor cells cannot be overlooked. This review provides a novel overview of the different aspects of the tumor cell response to AAT. Conflicting data regarding the nature of this effect are discussed and reconciled, thus providing new insight into the discussion of tumor recurrence despite AAT.

Citing Articles

Characterization and validation of a prognostic model for the N6-methyladenosine-associated ferroptosis gene in colon adenocarcinoma.

Liu X, An J, Wang Q, Jin H Transl Cancer Res. 2024; 13(8):4389-4407.

PMID: 39262465 PMC: 11384320. DOI: 10.21037/tcr-24-88.


Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.

Zaccagnino A, Vynnytska-Myronovska B, Stockle M, Junker K J Cell Mol Med. 2024; 28(9):e18329.

PMID: 38693863 PMC: 11063727. DOI: 10.1111/jcmm.18329.


Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer.

Takamatsu S, Nakai H, Yamaguchi K, Hamanishi J, Mandai M, Matsumura N JAMA Netw Open. 2023; 6(8):e2326834.

PMID: 37531111 PMC: 10398412. DOI: 10.1001/jamanetworkopen.2023.26834.


Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer.

Nakai H, Matsumura N Ann Transl Med. 2023; 11(5):229.

PMID: 37007537 PMC: 10061489. DOI: 10.21037/atm-22-6389.


An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.

Zaccagnino A, Vynnytska-Myronovska B, Stockle M, Junker K Int J Mol Sci. 2023; 24(6).

PMID: 36982721 PMC: 10058472. DOI: 10.3390/ijms24065648.